JPRN-jRCT2031230531招募中1 期
A Phase I study of Oxyfedrine and Sulfasalazine in Patients with Solid Tumor - FC001-P1 Study
Kohei Shitara0 个研究点目标入组 54 人开始时间: 2023年12月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Patients who have voluntarily provided written consent for participation in the study.
- •2.Patients aged 18 years or older at the time of providing informed consent.
- •3.Patients diagnosed with solid tumor who:
- •(Dose-escalation part)
- •Histologically or cytologically confirmed unresectable or recurrent solid tumor
- •(Dose-expansion part)
- •Histologically or cytologically confirmed unresectable or recurrent solid tumor to be one of the following
- •-Cohort A: Stomach cancer
- •-Cohort B: Renal cell carcinoma
- •-Cohort C: Triple negative breast cancer
- •4.Refractory or intolerant to conventional therapy
- •5.Measurable disease according to RECIST version 1.1
- •6.Patients with PS (ECOG) of 0 to 1
- •7.Life expectancy of at least 12 weeks
- •8.Patients who have adequate organ function and whose latest laboratory results within 7 days prior to enrollment meet all the following criteria.
- •-ANC >= 1500 /mm3
- •-Platelet count >= 100,000/ mm3
- •-Hemoglobin >= 9.0 g/dL
- •-Calculated (with the Cockcroft-Gault formula) or measured creatinine clearance >= 40 mL/min
- •-Total bilirubin <= 1.5XULN
- •-AST, ALT<=100 IU/L
- •9.Males and females of childbearing potential agree to use contraception from the time consent is obtained until at least 30 days after the last dose of study drug.
排除标准
- •1.Patients with a history of administration of sulfasalazine or 5-ASA preparations.
- •2.Patients receiving systemic beta-stimulants or beta-blockers (although temporary use of beta-stimulants for asthma attacks is acceptable).
- •3.Patients with symptomatic brain metastases or meningeal dissemination
- •4.Patients who are pregnant or breastfeeding
- •5.Patients with active overlapping cancers requiring treatment such as drug therapy or surgery.
- •However, patients with history of carcinoma situ which are considered to be cured by local treatment, lesions equivalent to intramucosal carcinoma or non-metastatic prostate cancer requiring systemic treatment are excluded.
- •6.Pateints who require the following anticancer therapy
- •-Any prior therapy (including chemotherapy, molecular targeted therapy, antibody therapy, hormone therapy or immune therapy) within 14 days before the start of the protocol treatment. However, bisphosphonate or denosumab for bone lesion, LH-RH agonist or GnRH antagonist for prostate cancer are allowed.
- •-Radiation therapy or Radiopharmaceutical therapy within 28 days before the start of the protocol treatment. However, palliative radiation therapy within 14 days before the start of theprotocol treatment is allowed.
- •7. Patients who have the following infectious diseases
- •- HBsAg-positive
- •-HBsAb-positive or HBcAb-positive
- •-HCVAb-positive
- •-HIV-positive
- •-Other active infectious diseases requiring treatment.
- •8. Patients with the following previous or current history
- •-Uncontrol ascites, pleural or pericardial effusion
- •-QT prolongation syndrome
- •-Interstitial pneumonia or pulmonary fibrosis
- •-Psychosis or propensity for medication overuse
- •-Hypersensitivity to sulfa drugs or salicylic acid preparations
- •-Hypersensitivity or serious adverse reactions to beta-stimulants
- •-Inflammatory bowel disease
- •9.Patients who are receiving systemic steroids or immunosuppressive drug therapy at enrollment.
- •Note : It is allowed in the following cases.
- •- A dose <= 10 mg / day of prednisolone
- •- Temporary use for testing or prophylactic administration for allergic reactions, or for reduction of edema associated with radiotherapy
- •10. Patients who does not have recovered from any adverse events (AEs) of previous anticancer therapy.
- •Note : Hematological abnormality meet inclusion criteria 6, CTCAE grade 2 peripheral neuropathy, alopecia, hyperpigmentation, and the cases judged by the investigator to have no safety problems are allowed.
- •11. Patients with myocardial infarction, congestive heart failure (New York Heart Association class III or IV), unstable angina or arrhythmia requiring treatment within 6 months prior to enrollment.
- •12. Patients who have a history of major surgery(minimal surgery is excluded, for example lymph node biopsy, core biopsy or implantation of port etc.) within 4 weeks prior to enrollment.
- •13. Patients who are unable to abstain from alcohol during the period of study drug administration.
- •14. Patients with other significant abnormalities.
- •15. Patients who are regarded as inappropriate for enrollment by investigators.
研究者
相似试验
招募中
Unknown
Tranlational Research: A Phase I study of Oxyfedrine and Sulfasalazine in Patients with Solid Tumorunresectable recurrent solid tumorJPRN-jRCT1030230529Shitara Kohei54
已完成
不适用
A Phase II Study of Olanzapine, Palonosetron and Dexamethasone for nausea and vomiting induced by the highly emetic chemotherapy including CisplatiMalignant tumor (lung cancer, gastric cancer, esophagus cancer, cervical cancer, endometrial cancer, head and neck cancer, etc)JPRN-UMIN000013482Aichi Cancer Center Hospital41
已完成
不适用
A study to evaluate the pharmacokinetic and pharmacodynamic equivalence of HSP-130 and United States-approved Neulasta (Registered Trademark) and European Union-approved Neulasta (Registered Trademark) administered as a single subcutaneous dose to healthy volunteers.The study will be conducted in healthy subjects. Neulasta is indicated for the treatment of cancer chemotherapy-induced neutropenia.Cancer - Any cancerACTRN12615001049561Hospira, Inc.150
已完成
2 期
A phase II study of oxaliplatin, folinic acid and 5-fluorouracil (modified FOLFOX-6) combination chemotherapy as adjuvant treatment after resection of liver metastases from colorectal cancerliver metastases of colorectal cancerJPRN-UMIN000000996Miyagi HBPCOG50
招募中
1 期
A pilot study of the pharmacokinetics, efficacy, and acceptability of a novel nicotine inhaler in smokersTobacco use disorderNicotine addictionMental Health - AddictionACTRN12606000423516Professor Julian Crane10